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Abstract
Background: Panic disorder has long been associated with the changes in various neurotransmitters, such as Neuropeptide-S (NPS). Objective: In this study 
we aimed to determine whether there is a relationship between blood NPS levels and panic disorder. Methods: Twenty nine patients with panic disorder and 
thirty two healthy control subjects who were age and gender matched were enrolled to the study. Blood samples were taken from participants and plasma NPS 
levels were quantified by using an ELISA kit. Results: In the study group, median NPS blood level was 16.7 pg/mL and in the control group it was 32.5 pg/mL. 
There was a statistically significant difference (p = 0.021). Using receiver operating characteristics (ROC) curve, sensitivity and specificity of NPS blood level, for 
diagnosing panic disorder was calculated, and it was found 79.3% and 56.25% respectively (AUC:0.672, 95% CI: 0.540-0.787). Discussion: Malfunction at the 
NPS modulatory system in the cortical areas (which is causing excitations in brain areas, such as amygdala and hypothalamus) does not only increase anxiety 
symptoms and risk of panic disorder but also causes panic disorder patients to have lower plasma NPS levels than the control group. Therefore it can be argued 
that such malfunction can be treated with a systemic treatment.
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Introduction
A panic attack is a sudden and unexpected rush of immense anxiety. 
It has a lifetime prevalence of 13.1%1. Not every patient who had a 
panic attack can be diagnosed with panic disorder. According to 
Diagnostic and Statistical Manual; a patient experiencing panic 
attacks can only be diagnosed as the panic disorder if that person 
is experiencing persistent anxiety about having more panic attacks 
and/or if these attacks are causing significant maladaptive changes 
in the behavior. Although two-thirds of the people who have panic 
attacks, experience them recurrently; only around one-sixth of them 
are eligible for panic disorder diagnosis1. 
Panic disorder has long been associated with various 
neurotransmitter signaling changes. In brief, there is a reduction 
of inhibitory signaling in the central nervous system among panic 
disorder patients. This postulate is backed up by the studies showing 
an increased function in glutamatergic neurons and decreased 
function in GABAergic neurons. There are also other monoamines 
(serotonin and noradrenaline) and neuropeptides (cholecystokinin) 
which have been associated with panic disorder as well2. 
Neuropeptide-S (NPS) was discovered around two decades 
ago. NPS has been shown to have several physiological roles; such 
as sleep regulation, modulation of feeding behavior, activation of 
the hypothalamic-pituitary-adrenal axis and adrenocorticotropic 
hormone (ACTH) release; extinguishing anxiety and conditioned 
fear responses3-5.
Animal  studies  have shown that  intranasa l 6-8 and 
intracerebroventricular7-10 NPS injections were able to reduce 
symptoms associated with anxiety and panic disorder. Also, 
Neuropeptide-S Receptor (NPSR) polymorphism has been shown 
to increase the risk of panic disorder both in animal and human 
studies3-5,10-18. However, there has been no study that examines the 
relationship between blood NPS levels and panic disorder up till now.
In this study, we aimed to determine whether there is a 
relationship between blood NPS levels and panic disorder. To 
examine this hypothesis, we quantified the plasma NPS levels of 
panic disorder patients and healthy controls. 
Methods
Subjects
We have designed our research as a case-control study. After getting 
an ethics committee approval we have prospectively enrolled 
participants to our study from January 2015 until December 2015. All 
the patients admitted to the Balikesir University Psychiatry outpatient 
service during 2015, who were diagnosed with panic disorder (either 
with or without agoraphobia) for the first time and who were not 
using any psychotropic or beta blocker drugs at the time of their 
admission, were asked to enroll to our study.
All the subjects, both the participants of study and control 
group, undergone structured interview of SCID (Structured 
Clinical Interview for DSM-IV). Medical history of all the 
participants were self declared. Their drug history were verified 
with the Republic of Turkey Social Security Institution’s online 
pharmaceutical database. 
Participants of the study group were excluded if they were 
given any other psychiatric diagnosis other than panic disorder. 
Additionally, participants of the control group were excluded 
from the study if any psychiatric diagnosis was given. Using any 
psychotropic or beta blocker drug was an exclusion criterion for 
all subjects.
Twenty-nine panic disorder patients who met criteria mentioned 
above agreed to participate in our study and gave a written informed 
consent. Thirty-two, age and gender matched healthy volunteers 
were enrolled to the study for the control group. This research was 
approved by the Balikesir University School of Medicine Clinical 
Research Ethics Committee on 10/01/2014 with the approval number 
2014/03.
Psychiatric scales
All participants were asked to fill the Panic and Agoraphobia 
Scale (PAS). PAS is a self-rated Likert type scale in which total 
scores can vary between 0 and 52. PAS measures panic attacks, 
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agoraphobia, anticipatory anxiety, disability, and worries among 
panic attack patients, either with or without agoraphobia. Even 
though PAS is not intended as a diagnostic instrument, it is a 
convenient tool to separate panic disorder patients from healthy 
individuals. Validity and reliability of the Turkish version of PAS 
has been established19.
Blood samples
Blood samples were taken from participants to determine the blood 
level of NPS. Fasting venous blood samples were extracted and were 
collected in EDTA tubes (Becton, Dickinson, USA). Samples were 
centrifuged at 1300 ×g for 10 minutes for plasma separation. Plasma 
samples and 1% concentrated protease inhibitor cocktail (Sigma 
Aldrich product number: P8340) were mixed in Eppendorf tubes. 
These mixtures were stored at -20°C while waiting for the further 
processing. NPS was quantified by using a commercial Human NPS 
(Neuropeptide S) ELISA kit (Wuhan Fine Biological Technology 
Company Ltd., China).
Statistics
All statistic analyses were made on SPSS version 15.0 (SPSS, Chicago, 
IL, USA). To determine the sensitivity and specificity of the blood 
level of NPS for diagnosing panic disorder ROC curve was made an 
area under the curve was calculated.
Results
Mean age of the study and control groups were 38.6 ± 9.0 years and 
39.3 ± 9.3 years respectively. There was no statistically significant 
difference between the two groups (p = 0.768).
The panic disorder group consisted 71.9% of females whereas 
control group consisted 86.2% of females. There was no statistically 
significant difference regarding the gender between two groups 
(p = 0,172). 
In the panic disorder group, median NPS plasma level was 16.7 
pg/mL, with a minimum of 3.7 and a maximum of 99.3. In the control 
group, median NPS blood level was 32.5 pg/mL, with a minimum 
of 3 and maximum of 156.1. A statistically significant difference 
was observed between the two groups (p = 0.021) (Figure 1). There 
was not a statistically significant correlation between PAS scores 
and blood NPS levels (rs = -0.232, p = 0.072). Optimal cut off score 
for NPS blood level was found 18.28 with the receiver operating 
characteristics (ROC) curve. Using that cut-off score; sensitivity and 
specificity of NPS blood level were calculated for diagnosing panic 
disorder. The results were 79.3% and 56.25% respectively (AUC:0.672, 
95% CI: 0.540-0.787) (Figure 2). 
Discussion
NPS is a, recently discovered, neurotransmitter which consists of 20 
amino acids. Since NPS has been uncovered, it has been associated 
with different physiological systems and attributed to various 
functions such as sleep regulation, modulation of feeding behavior, 
activation of the hypothalamic-pituitary-adrenal axis and release of 
adrenocorticotropic hormone (ACTH); extinguishing anxiety and 
conditioned fear responses3-5. Even though expression of NPS is 
mostly limited to brainstem areas, mRNA of the NPS receptor (NPSR) 
has been demonstrated to be widely expressed in various brain 
regions, including olfactory regions and amygdala, hippocampal 
formation, and hypothalamus4. 
At the first glance, the data on the relationship between NPS and 
panic disorder can give the impression that it is contradictory. On 
the one hand, NPS has crucial functions in extinguishing anxiety 
and conditioned fear responses3-5, and administration of NPS 
(both intranasally and intracerebroventricularly) has anxiolytic 
properties6-10. On the other hand, NPS has been shown to activate 
hypothalamic-pituitary-adrenal axis and increases the release of 
ACTH3-5 and mutations that make NPSR more active, for both single 
nucleotide polymorphisms and mutations at the promoter sequence, 
causes subjects to be more susceptible to have panic disorder3-5,10-17.
The modulatory function of the NPS and NPSR explains the 
findings mentioned in the previous paragraph3-5. NPSR is mainly 
found on glutamatergic neurons, which are excitatory. However, 
these glutamatergic neurons mostly innervate GABAergic 
interneurons, especially in the amygdala. Overall NPSR activation 
causes inhibition in brain areas such as the amygdala. Therefore NPS 
has a modulatory role rather than a straightforward inhibitory or 
excitatory function3-5,10,11. 
The neuroimaging studies support the discussions mentioned 
above. Human neuroimaging studies done by fMRI demonstrated 
that subjects who carried a mutated T allele for the rs324981 
polymorphism in NPSR-1 gene showed increased activity in 
especially amygdala and prefrontal cortex. This increased activity 
is thought to cause a higher risk for anxiety and panic disorders13-18.
So far there has not been any study which investigated the 
relationship between plasma NPS levels and panic disorder. Most of 
the human studies on the subject looked into polymorphisms in the 
genes which are coding NPS and NPSR. Moreover, animal studies 
quantified NPS and NPSR mRNA in the brain tissue of mice and rats, 
on top of investigating similar polymorphisms mentioned earlier. 
However, our study brings forward a new approach to the subject. 
Our hypothesis was, there would be a statistically significant 
difference in plasma NPS levels between panic disorder and control 
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Figure 2. ROC curve of sensitivity and 100-specificity of NPS blood level 
for diagnosis of panic disorder.
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modulatory system in the cortical areas, panic disorder patients had 
lower plasma NPS levels than the control group. It can be argued 
that such malfunction can be treated with a systemic treatment. 
Hence intranasal administration of NPS was found to have anxiolytic 
properties, as it was mentioned previously.
Although there was a statistically significant difference between 
two groups in plasma NPS level, there was no relevant relationship 
between the PAS scores and blood NPS levels. These results can be 
caused by the size of our study. Moreover, PAS has five sub-scores 
but a total of 14 questions, which decreases the reliability of the test 
and caused the results reached. 
Major limitation of our study was our small sample size which 
may have resulted in decreased statistical significance in our results. 
Moreover, small sample size limited our ability to obtain gender 
specific results. Although among female participants there was a 
statistically significant difference of plasma NPS levels between 
subject and control groups, there was no such difference among male 
participants. From the total of 61 participants, only 13 being men 
may have caused this result.
Furthermore, one blood sample was taken at the first admission 
to our outpatient service. Obtaining more samples from participants, 
including after sufficient treatment, can give us a better opinion on 
the trajectory of NPS throughout the progress and resolution of the 
disorder. Even though PAS is an established measurement of various 
sub-scales mentioned in the methods section; future researches 
can enhance study the design by including other panic or anxiety 
scales, such as Hamilton Anxiety Rating Scale and Panic Disorder 
Severity Scale.
In conclusion, NPS plasma levels of the panic disorder patients 
are found to be significantly lower than the control group. This result 
can be interpreted as a possible malfunction at the modulatory NPS 
system in panic disorder patients which causes NPS levels to be 
lower than the healthy population. Impaired NPS production and 
therefore function are producing excitations in brain areas, such as 
the amygdala, which results in anxiety symptoms and increased risk 
of panic disorder. Our findings are in line with the previous studies 
and take us a step closer to comprehending the roles of NPS in panic 
disorder and its possible use for the treatment of the disease.
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